European Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer

July 23, 2025/0 Comments/in FDA approvals/by Max

The European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]